Preclinical study demonstrates directed complement activation targeting tumor cells in HER2 breast cancer, suggesting an alternative therapy against treatment resistance.
We showed here that directed complement activation on tumor cells is an alternative to therapeutic antibodies for future combination therapies upon resistance to standard-of-care treatment.
No takes yet. Share an insight, caveat, or question.
Seguin‐Devaux et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: